drugset
drugset / Trial / NCT03817476

A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood

NCT03817476 ↗

Phase 1 Completed 18 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The main objective of this trial is to investigate the relative bioavailability of batch 1 of the intended commercial tablet formulation (iCF1) of BI 425809 vs batch 2 of the intended commercial tablet formulation (iCF2) of BI 425809 vs BI 425809 (TF2) formulation.

Timeline

Start
2019-02-11
Primary completion
2019-05-28
Completion
2019-05-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Iclepertin Small molecule 25 mg Oral

Indications

No indication recorded.